Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
- PMID: 23376471
- DOI: 10.1016/j.freeradbiomed.2013.01.017
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
Abstract
Brain iron accumulation has been implicated in a host of chronic neurological diseases, including Parkinson's disease (PD). The elevated iron levels observed in the substantia nigra of PD subjects have been suggested to incite the generation of reactive oxygen species and intracellular α-synuclein aggregation, terminating in the oxidative neuronal destruction of this brain area. Thus, elucidation of the molecular mechanisms involved in iron dysregulation and oxidative stress-induced neurodegeneration is a crucial step in deciphering PD pathology and in developing novel iron-complexing compounds aimed at restoring brain iron homeostasis and attenuating neurodegeneration. This review discusses the involvement of dysregulation of brain iron homeostasis in PD pathology, with an emphasis on the potential effectiveness of naturally occurring compounds and novel iron-chelating/antioxidant therapeutic hybrid molecules, exerting a spectrum of neuroprotective interrelated activities: antioxidant/monoamine oxidase inhibition, activation of the hypoxia-inducible factor (HIF)-1 signaling pathway, induction of HIF-1 target iron-regulatory and antioxidative genes, and inhibition of α-synuclein accumulation and aggregation.
Keywords: 6-OHDA; 6-hydroxydopamine; AD; ALS; Alzheimer's disease; BBB; Brain; DFO; EGCG; EPO; F-box/leucine-rich repeat protein 5, GLUT, glucose transporter; FBXL5; Free radicals; GSH; HIF; HO-1; IRE; Iron; Iron chelation; L-DOPA; MAO; MPTP; N-methyl-4-phenyl-1,2,3,6-tertahydropyridine; Neuroprotection; OS; PD; PHD; Parkinson's disease; ROS; SNpc; SOD; TH; Tf; TfR; UPDRS; UPS; Unified Parkinson's Disease Rating Scale; VEGF; amyotrophic lateral sclerosis; blood–brain barrier; desferrioxamine; epigallocatechin 3-gallate; erythropoietin; glutathione; heme oxygenase-1; hypoxia-inducible factor; iron-responsive element; l-dihydroxyphenylalanine; monoamine oxidase; oxidative stress; prolyl-4-hydroxylase; reactive oxygen species; substantia nigra pars compacta; superoxide dismutase; transferrin; transferrin receptor; tyrosine hydroxylase; ubiquitin–proteasome system; vascular endothelial growth factor..
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.J Mol Neurosci. 2004;24(3):401-16. doi: 10.1385/JMN:24:3:401. J Mol Neurosci. 2004. PMID: 15655262
-
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Free Radic Biol Med. 2013. PMID: 23743292 Review.
-
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?J Neural Transm Suppl. 2003;(65):73-88. doi: 10.1007/978-3-7091-0643-3_5. J Neural Transm Suppl. 2003. PMID: 12946050 Review.
-
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.Ann N Y Acad Sci. 2004 Mar;1012:306-25. doi: 10.1196/annals.1306.025. Ann N Y Acad Sci. 2004. PMID: 15105275
-
The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.Gene. 2013 Dec 10;532(1):18-23. doi: 10.1016/j.gene.2013.07.085. Epub 2013 Aug 15. Gene. 2013. PMID: 23954870 Review.
Cited by
-
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.Nat Rev Drug Discov. 2018 Nov;17(11):804-822. doi: 10.1038/nrd.2018.136. Epub 2018 Sep 28. Nat Rev Drug Discov. 2018. PMID: 30262889 Review.
-
Evaluation of the Antioxidant and Neuroprotectant Activities of New Asymmetrical 1,3-Diketones.Molecules. 2018 Jul 24;23(8):1837. doi: 10.3390/molecules23081837. Molecules. 2018. PMID: 30042315 Free PMC article.
-
Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. J Neural Transm (Vienna). 2020. PMID: 31912279 Review.
-
Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism.Int J Mol Sci. 2019 Jul 3;20(13):3274. doi: 10.3390/ijms20133274. Int J Mol Sci. 2019. PMID: 31277285 Free PMC article. Review.
-
Eryptosis as a marker of Parkinson's disease.Aging (Albany NY). 2014 Oct;6(10):788-819. doi: 10.18632/aging.100695. Aging (Albany NY). 2014. PMID: 25411230 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous